22
https://pubmed.ncbi.nlm.nih.gov/38112492
Researchers have developed a new compound, OY3, that lowers bad cholesterol by targeting and degrading PCSK9, a protein associated with high cholesterol, and shows improved efficacy over simvastatin in treating atherosclerosis.